ORGENESIS INC (ORGS) Financials
A multiple compares the market's price with a filed figure; it says what the market pays, not how the business is doing. The market capitalization is the vendor's as of Oct 13, 2026; every other figure is from the SEC filings on this page. Not financial advice.
Newest figures come from the 10-K for FY2024, filed Mar 26, 2026. Each column of the statement tables below links to the filing it was taken from, and every filing is listed on the ORGS SEC filings page.
ORGENESIS INC (ORGS) reported $1.0M in revenue for fiscal year 2024, up 95.3% from the prior fiscal year. This page shows its income statement, balance sheet, cash flow statement, and key financial ratios. View 15 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).
The business has shrunk to very low revenue while liabilities remain large, leaving a balance sheet financed more by obligations than operating scale.
Revenue collapsed after FY2022, and reported gross margin moved from positive to negative by FY2024; this points to a business no longer covering direct costs at its smaller scale. Meanwhile, liabilities increased while assets fell from FY2023 to FY2024, showing balance-sheet deterioration that was not merely a consequence of weaker sales.
FY2024 revenue was
By FY2024, total liabilities were
Financial Health Signals
ORGENESIS INC does not currently provide enough eligible data for a peer-relative financial health score, so none is published. The metrics below are current.
Key Financial Metrics
Earnings & Revenue
ORGENESIS INC generated $301K in revenue in Q4 2024. This represents an increase of 82.4% from the same quarter a year earlier. Against the prior quarter it is down 13.3%.
Not reported for Q4 2024.
Not reported for Q4 2024.
Not reported for Q4 2024.
Cash & Balance Sheet
ORGENESIS INC recorded an outflow of $2.1M in free cash flow in Q4 2024, representing a cash shortfall after capex. This represents a decrease of 317.9% from the same quarter a year earlier. Against the prior quarter it is up 55.2%.
ORGENESIS INC held $78K in cash as of Q4 2024; long-term debt is not reported for that period.
Not reported for Q4 2024.
Margins & Returns
ORGENESIS INC's gross margin was -4.0% in Q4 2024, indicating the percentage of revenue retained after direct costs. This is down 5.8 percentage points from the same quarter a year earlier. Against the prior quarter it is up 64.6 percentage points.
Not reported for Q4 2024.
Not reported for Q4 2024.
Not reported for Q4 2024.
Capital Allocation
ORGENESIS INC reported no capital expenditure in Q4 2024. Against the prior quarter it is down 100.0%.
Not reported for Q4 2024.
Not reported for Q4 2024.
ORGS Income Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q4'2410-K | Q3'2410-Q | Q2'2410-Q | Q1'2410-Q | Q4'2310-K | Q3'2310-Q | Q2'2310-Q | Q1'2310-Q |
|---|---|---|---|---|---|---|---|---|
| Revenue | $301K+82.4% | $347K+215.5% | $246K+117.7% | $141K-0.7% | $165K-98.7% | $110K-98.6% | $113K-98.4% | $142K-98.0% |
| Cost of Revenue | $313K+93.2% | $585K+320.9% | $538K-83.4% | $492K-81.9% | $162K-93.2% | $139K-85.9% | $3.2M+204.0% | $2.7M+281.2% |
| Gross Profit | -$12K-500.0% | -$238K-720.7% | -$292K+90.6% | -$351K+86.4% | $3K-100.0% | -$29K-100.4% | -$3.1M-150.8% | -$2.6M-139.7% |
| R&D Expenses | N/A | $4.5M+459.8% | $1.5M-57.8% | $2.4M-27.8% | $3.0M-20.0% | $808K-78.1% | $3.5M-55.0% | $3.3M-50.7% |
| SG&A Expenses | N/A | $2.7M+114.0% | $2.1M-88.7% | $6.1M-55.2% | $2.1M-68.6% | $1.2M-59.9% | $18.2M+549.9% | $13.5M+374.5% |
| Operating Income | N/A | -$8.4M-275.6% | -$4.3M+83.0% | -$8.9M+54.4% | -$6.7M-261.9% | -$2.2M-695.4% | -$25.1M-429.8% | -$19.6M-505.6% |
| EBITDA | N/A | -$7.9M-284.3% | -$3.5M+85.5% | -$8.5M+55.0% | -$6.5M-386.0% | -$2.0M-1087.4% | -$24.5M-478.4% | -$19.0M-588.6% |
| Income Tax | $44K+131.2% | $32K-91.9% | $5K-94.5% | $16K-87.6% | -$141K-182.0% | $394K+1476.0% | $91K+727.3% | $129K+12800.0% |
| Net Income | N/A | -$9.1M-144.8% | -$8.9M+65.1% | -$9.8M+49.8% | -$6.6M-61.7% | -$3.7M-174.7% | -$25.5M-370.7% | -$19.5M-385.7% |
| EPS (Basic) | N/A | $1.93+1508.3% | $0.23-69.7% | $0.29-66.7% | $0.21+31.2% | $0.12+140.0% | $0.76+245.5% | $0.87+443.8% |
| EPS (Diluted) | N/A | $1.93+1508.3% | $0.23-69.7% | $0.29-66.7% | $0.21+31.2% | $0.12+140.0% | $0.76+245.5% | $0.87 |
| Diluted Shares (Avg) | N/A | 5M+57.1% | 39M+35.9% | 33M+25.3% | N/A | 3M-88.2% | 29M+15.2% | 26M |
Not reported in any period shown, so not listed: Interest Expense.
ORGS Balance Sheet
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q4'2410-K | Q3'2410-Q | Q2'2410-Q | Q1'2410-Q | Q4'2310-K | Q3'2310-Q | Q2'2310-Q | Q1'2310-Q |
|---|---|---|---|---|---|---|---|---|
| Total Assets | $1.4M-90.7% | $29.7M+69.3% | $30.6M+69.2% | $30.9M-58.3% | $14.6M-84.0% | $17.5M-75.2% | $18.1M-71.2% | $74.2M+26.7% |
| Current Assets | $761K-81.3% | $2.5M-57.9% | $2.3M-64.1% | $2.0M-93.6% | $4.1M-91.2% | $6.0M-81.2% | $6.5M-74.3% | $30.3M+26.3% |
| Cash & Equivalents | $78K-90.7% | $204K+270.9% | $77K-57.2% | $80K-97.0% | $837K-84.2% | $55K-98.2% | $180K-92.2% | $2.7M+138.1% |
| Short-Term Investments | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Inventory | N/A | N/A | N/A | $34K-73.4% | $34K-71.7% | $34K-64.2% | $34K-68.2% | $128K+13.3% |
| Accounts Receivable | $40K-54.5% | $161K+126.8% | $240K+3900.0% | $245K-98.9% | $88K-99.8% | $71K-99.7% | $6K-100.0% | $21.3M+25.0% |
| Long-Term Investments | $0-100.0% | $0-100.0% | $0-100.0% | $8K-94.1% | $8K-79.5% | $31K | $41K | $136K |
| Goodwill | N/A | $1.2M0.0% | $1.2M0.0% | $1.2M-85.0% | $1.2M-85.2% | $1.2M-84.4% | $1.2M-85.2% | $8.1M-3.1% |
| Total Liabilities | $38.9M+9.4% | $53.6M+63.0% | $46.4M+50.5% | $58.5M-10.6% | $35.5M-43.9% | $32.9M-18.6% | $30.8M-0.5% | $65.4M+176.3% |
| Current Liabilities | $26.9M+64.1% | $36.0M+152.1% | $31.7M+149.4% | $29.0M+108.3% | $16.4M+3.1% | $14.3M-58.1% | $12.7M-21.8% | $13.9M-8.6% |
| Non-Current Liabilities | $12.0M-37.5% | $17.6M-5.6% | $14.7M-18.9% | $29.4M+47.0% | $19.1M+21.5% | $18.6M+196.6% | $18.1M+23.0% | $20.0M+137.6% |
| Total Equity | -$37.5M-78.7% | -$23.9M-55.5% | -$15.5M-21.7% | -$27.7M-418.0% | -$21.0M-176.1% | -$15.4M-150.9% | -$12.7M-140.1% | $8.7M-74.9% |
| Retained Earnings | -$224.8M-27.3% | -$204.4M-20.2% | -$195.3M-17.5% | -$186.4M-32.4% | -$176.6M-45.7% | -$170.0M-45.1% | -$166.3M-43.6% | -$140.7M-27.5% |
Not reported in any period shown, so not listed: Long-Term Debt.
ORGS Cash Flow Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q4'2410-K | Q3'2410-Q | Q2'2410-Q | Q1'2410-Q | Q4'2310-K | Q3'2310-Q | Q2'2310-Q | Q1'2310-Q |
|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -$2.1M-317.9% | -$4.6M-292.0% | -$5.9M+0.1% | -$4.4M+38.7% | -$502K+95.3% | -$1.2M+76.2% | -$5.9M+7.8% | -$7.2M-159.3% |
| Depreciation & Amortization | $461K+137.6% | $538K+181.7% | $706K+18.3% | $381K-34.1% | $194K-62.3% | $191K-60.9% | $597K+19.2% | $578K+21.9% |
| Stock-Based Compensation | N/A | N/A | N/A | $312K+96.2% | N/A | N/A | N/A | $159K-40.7% |
| Capital Expenditures | $0 | $58K-80.7% | $1K-99.8% | $204K-84.1% | $0-100.0% | $300K-88.5% | $511K-85.2% | $1.3M+42.5% |
| Free Cash Flow | -$2.1M-317.9% | -$4.7M-216.5% | -$5.9M+8.0% | -$4.6M+45.5% | -$502K+96.9% | -$1.5M+80.5% | -$6.4M+34.9% | -$8.5M-130.8% |
| Investing Cash Flow | $292K+571.0% | $142K+116.8% | -$1K+99.9% | -$68K+94.8% | -$62K+99.1% | -$843K+67.5% | -$1.5M+54.0% | -$1.3M+19.0% |
| Financing Cash Flow | $1.4M+14.2% | $4.4M+177.7% | $6.5M+33.3% | $3.6M-38.8% | $1.2M-93.7% | $1.6M-82.6% | $4.9M-55.2% | $5.9M+590900.0% |
Not reported in any period shown, so not listed: Dividends Paid, Share Buybacks.
ORGS Financial Ratios
Margins and returns are percentages; the remaining ratios are unitless multiples. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q4'2410-K | Q3'2410-Q | Q2'2410-Q | Q1'2410-Q | Q4'2310-K | Q3'2310-Q | Q2'2310-Q | Q1'2310-Q |
|---|---|---|---|---|---|---|---|---|
| Gross Margin | -4.0%-5.8pp | -68.6%-42.2pp | -118.7% | -248.9% | 1.8%-89.4pp | -26.4%-114.1pp | -2760.2% | -1816.9% |
| Operating Margin | N/A | -2419.0% | -1727.6% | -6333.3% | -4081.8% | -2031.8% | -22185.8% | -13800.0% |
| Net Margin | N/A | -2628.2% | -3619.5% | -6925.5% | -4013.9% | -3386.4% | -22604.4% | -13711.3% |
| Return on Equity | N/A | N/A | N/A | N/A | N/A | N/A | N/A | -223.4%-211.9pp |
| Return on Assets | N/A | -30.7%-9.5pp | -29.1%+112.2pp | -31.6%-5.3pp | -45.5%-41.0pp | -21.3%-19.3pp | -141.4%-132.7pp | -26.3%-19.4pp |
| Current Ratio | 0.03-0.2x | 0.07-0.3x | 0.07-0.4x | 0.07-2.1x | 0.25-2.7x | 0.42-0.5x | 0.51-1.1x | 2.18+0.6x |
| Debt-to-Equity | N/A | N/A | N/A | N/A | N/A | N/A | N/A | 7.51+6.8x |
| Asset Turnover | 0.22+0.2x | 0.010.0x | 0.010.0x | 0.000.0x | 0.01-0.1x | 0.01-0.1x | 0.01-0.1x | 0.00-0.1x |
| FCF Margin | -697.0% | -1351.0% | -2401.6% | -3294.3% | -304.2% | -1346.4% | -5685.8% | -6003.5% |
Reported as filed but not readable as a share of revenue in the periods where the ratio runs further from zero than a revenue base allows; no change figure is given where either compared period is one of those: Gross Margin, Operating Margin, Net Margin, FCF Margin.
Note: Shareholder equity is negative (-$37.5M), which causes debt-to-equity and return on equity ratios to appear negative or not meaningful. This can occur from accumulated losses or large share buyback programs.
Note: The current ratio is below 1.0 (0.03), indicating current liabilities exceed current assets, which may suggest potential short-term liquidity concerns.
Similar Companies
Newest fiscal year on record for each company. The health score is the peer-relative Financial Health Score for that year; a dash means no score is published for it.
| Company | Fiscal year | Revenue | Net income | Net margin | Market cap | Health score |
|---|---|---|---|---|---|---|
| ORGENESIS INC ORGS | FY2024 | $1.0M | N/A | N/A | $3.4M | — |
| VAXXINITY INC A VAXX | FY2023 | N/A | -$56.9M | N/A | $13.9M | — |
Where ORGENESIS INC Ranks
Frequently Asked Questions
What is ORGENESIS INC's annual revenue?
ORGENESIS INC (ORGS) reported $1.0M in total revenue for fiscal year 2024. This represents a 95.3% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.
How fast is ORGENESIS INC's revenue growing?
ORGENESIS INC (ORGS) revenue grew by 95.3% year-over-year, from $530K to $1.0M in fiscal year 2024.
What is ORGENESIS INC's gross margin?
ORGENESIS INC (ORGS) had a gross margin of -86.3% in fiscal year 2024, indicating the percentage of revenue retained after direct costs of goods sold.
What are ORGENESIS INC's total assets?
ORGENESIS INC (ORGS) had $1.4M in total assets as of fiscal year 2024, including both current and long-term assets.
What are ORGENESIS INC's capital expenditures?
ORGENESIS INC (ORGS) invested $263K in capital expenditures during fiscal year 2024, funding long-term assets and infrastructure.
What is ORGENESIS INC's current ratio?
ORGENESIS INC (ORGS) had a current ratio of 0.03 as of fiscal year 2024, which is below 1.0, which may suggest potential liquidity concerns.
What is ORGENESIS INC's P/E ratio?
ORGENESIS INC (ORGS) has no price-to-earnings ratio at the moment: no net income reported. The market capitalization is $3.4M as of Oct 13, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.
What is ORGENESIS INC's price-to-sales ratio?
ORGENESIS INC (ORGS) trades at 3.3x sales, its market capitalization divided by revenue of $1.0M revenue, FY2024. The market capitalization is $3.4M as of Oct 13, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.
Why is ORGENESIS INC's debt-to-equity ratio negative or not reported?
ORGENESIS INC (ORGS) has negative shareholder equity of -$37.5M as of fiscal year 2024, so no debt-to-equity ratio is reported: dividing debt by equity that is not positive produces a number that cannot be read as leverage. This can occur when accumulated losses exceed invested capital, or after large share buyback programs. Other solvency metrics like the current ratio or interest coverage may be more informative.